Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (125)

« Back to Publications

Molnupiravir Treatment for COVID-19 in People at Higher Risk in the Community: Outcomes from the PANORAMIC Randomised Controlled Trial at Three and Six Months

Harris V. et al, (2026)

Impact of the COVID-19 Lockdown on Admissions and Mortality in Children Admitted to Four Referral Hospitals in Durban, South Africa

Naidoo KL. et al, (2026)

Nirmatrelvir–ritonavir versus usual care in at-risk adults with early SARS-CoV-2 infection in the UK, 2022–23: virological and immunological results of an open-label randomised trial (PANORAMIC)

Lowe DM. et al, (2026), Lancet Microbe, 7

Cardiovascular Disease Risk in Low- and MIddle-income countries: better data for better evidence.

Dorward J. et al, (2026), Clin Infect Dis

Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients

Butler CC. et al, (2026), New England Journal of Medicine, 394, 1583 - 1594

Inflammatory Biomarkers Predicting Major Adverse Cardiovascular Events in People Living With HIV: A Systematic Review and Meta-Analysis

Murray A. et al, (2026), Journal of the International AIDS Society, 29

Association between pharmacological tenofovir adherence measures and subsequent 24-week viral load outcomes for people with HIV in South Africa.

Bodley N. et al, (2026), J Acquir Immune Defic Syndr

Risk of Major Adverse Cardiovascular Events With Dolutegravir Versus Efavirenz-Based Antiretroviral Therapy: Emulated Target Trials Using Routine, De-Identified Data From South Africa.

Dorward J. et al, (2026), Clin Infect Dis

Risk of Major Adverse Cardiovascular Events With Dolutegravir Versus Efavirenz-Based Antiretroviral Therapy: Emulated Target Trials Using Routine, De-Identified Data From South Africa.

Dorward J. et al, (2026), Clin Infect Dis

Point-of-care HIV viral load testing in a community antiretroviral therapy delivery programme: A randomised controlled trial (PHILA)

Dorward J. et al, (2026), Plos Global Public Health, 6

Quality assessment of data for decentralised antiretroviral therapy referrals and laboratory results in the South African national electronic HIV management register TIER.Net

Naidu L. et al, (2026), Plos Global Public Health, 6

Acceptability and perspectives on clinic-based urine tenofovir testing for antiretroviral therapy adherence monitoring: qualitative findings from a randomized controlled trial in South Africa

Bardon AR. et al, (2026), AIDS Care Psychological and Socio Medical Aspects of AIDS HIV

Association between pharmacological tenofovir adherence measures and subsequent 24-week viral load outcomes for people living with HIV in South Africa

Bodley N. et al, (2025)

Uptake and 24-month Outcomes of Dolutegravir- Versus Lopinavir-based Second-line Antiretroviral Therapy for People With HIV in South Africa: A Retrospective Cohort Study and Emulated Target Trial

Brown JA. et al, (2025), Open Forum Infectious Diseases, 12

The PRINCIPLE randomised controlled open label platform trial of hydroxychloroquine for treating COVID19 in community based patients at high risk

Hobbs FDR. et al, (2025), Scientific Reports, 15

Load More

1
2
3
4
5
6
7
...
»